Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
Date:4/30/2009

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2009 financial results after the market closes on Thursday, May 7, 2009.

Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, May 7, 2009 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-856-1961 (domestic) or 719-325-4792 (international). To access the webcast, please visit the company's website at and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...icular cancer who were treated with cisplatin-base...ding neurological side effects and Raynaud-like ph...herapy, according to a new study published online ... Institute . , Marianne Brydy, M.D., of the Depa... in Bergen, Norway, and colleagues conducted a cro...
(Date:11/25/2009)...at grew out of a collaboration between UCLA engine... the nearly 10 million Americans who suffer from p...hardening of the arteries, peripheral arterial dis...hich narrowed arteries reduce blood flow to the li...scular disease, heart attack and stroke, and its p...
(Date:11/25/2009)...s too short to draw definite conclusions, experts ...News) -- In diabetic patients with blocked coronar...utcomes at one year whether patients undergo bypas...searchers report. , Bypass surgery has been the...onary artery disease. However, less invasive appro...
(Date:11/25/2009)...luation and treatment clinics to resume Monday, No... November 25, 2009 -- Centegra Health System is co...cine shots at four Centegra Primary Care (CPC) vac... has arrived. The clinics are at CPC sites in Hunt...be open as follows: ,   From 4:30 to 7...
(Date:11/25/2009)...urological symptoms, study finds , , WE...side effects are among the potential problems face...were treated with cisplatin-based chemotherapy, a ... Norwegian men treated for unilateral testicular c...low-up survey conducted from 1998 to 2002. , Th...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...shington – Today, the nursing profession is sought...reign countries has made the noble profession,// l...to foreign lands, in search of greener pastures. T...omeland to find work in the Unites States. In the ...
... a tragic mistake, the young life of John Mealey, ... infection for a simple// hangover. Describin... centre for excellence for this very type of condi...y was admitted to Aintree Hospitals NHS Trust - a ...
...w Haven, Conn. — Recurring chlamydia infections ar...o a Yale Department of Epidemiology and Public Hea...istant professor in the division of Epidemiology o...osed with chlamydia and then, in a rate higher tha...
...tamin A deficiency has resulted in blindness among...of India, a study has found.// As much as 51... blind in that region have become blind over a per...the North East, a study reveals. There is a sing...
...top drug regulator told lawmakers Monday it could ... safely approve generic versions of biotech drugs ...ditional drugs. Food and Drug Administration d... in the U.S. for their products, some of the most ...
...premier Indian medical institution failed to infor...positive. The girl paid for its callousness//, wit...channel. 17-year-old Jyoti, was the daughter of ...Medical Sciences (AIIMS), a prestigious institutio...
Other Medicine News:Health News:‘Drunk’ Doctors Misdiagnosis Proves Fat 2Health News:Recurring Chlamydia Infections Common in Teenage Girls 2Health News:FDA Cites Challenges of Generic Biotech 2Health News:Patient Pays For The Callousness Of Hospital Administration 2
(Date:11/25/2009)...,, NEWYORK,Nov.25/PRNewswire/--Reportlinker.com...itscatalogue: ,, UnitedStatesDentalDevicesMark...portlinker.com/p0158733/United-States-Dental-Devic..., UnitedStatesDentalDevicesMarketAnalysisandForec...entialsourceforin-depthinformationanddatarelatingt...
(Date:11/25/2009)...,, SANDIEGO,Nov.25/PRNewswire-FirstCall/--NuVas...edondevelopingproductsforminimallydisruptivesurgic...staconferencecallonMonday,November30,2009,at5:30p....tissuesrelativetoreimbursementfortheCompany,sprodu...shortquestionandanswersession.Thedial-innumbersare...
(Date:11/25/2009)...,, FRAMINGHAM,Mass.andSYDNEY,Nov.25/PRNewswire-...WR ;ASX:HIN),aleadinginnovatorandprovideroflessinv...volutionizingthetreatmentofadvancedheartfailure,to...ntationatthe21stAnnualPiperJaffrayHealthCareConfer...renceisbeingheldattheNewYorkPalaceHotel,December1-...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Families With Special Needs Children Need Special Financial Strategies 53581 1Families With Special Needs Children Need Special Financial Strategies 53581 2Families With Special Needs Children Need Special Financial Strategies 53581 3Sustainable agriculture at the ESA Annual Meeting 9466 1Sustainable agriculture at the ESA Annual Meeting 9466 2Sustainable agriculture at the ESA Annual Meeting 9466 3Sustainable agriculture at the ESA Annual Meeting 9466 4FDA selects Sensotech 26apos 3Bs Wireless Temperature Monitoring System 53576 1FDA selects Sensotech 26apos 3Bs Wireless Temperature Monitoring System 53576 2
...Hit Therapeutics,(Alternext: ALEHT) is pleased to ...d compound in Alzheimer,s disease, is progressing ...sessing EHT 0202 in patients with,Alzheimer,s dise... of patient enrolment for the Phase IIa,represents...0202, and,provides a clear timeline for the releas...
...o long for surgery, study finds , , LAS VEGAS, Fe... to have poorer joint function before undergoing h... study presented today at the 2009 Annual Meeting ...(AAOS) ( http://www.aaos.org/ ). In addition, fema...than male patients across ethnic groups. , , "Stu...
Other Medicine Technology:ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4When to Have That Joint Replacement? 2When to Have That Joint Replacement? 3
O-arm Complete Multidimensional Surgical Imaging
ABX Micros IM Hematology Analyzers
Rio™ Aspiration Catheter
Sound Pro Combination Table
Medicine Products: